- Home
- CTO vs CRMD Comparison
CTO vs CRMD Comparison
Compare CTO & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTO | CRMD |
|---|---|---|
| Founded | 1902 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 552.9M | 876.7M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | CTO | CRMD |
|---|---|---|
| Price | $17.73 | $11.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $22.00 | $17.43 |
| AVG Volume (30 Days) | 237.6K | ★ 3.0M |
| Earning Date | 10-28-2025 | 11-12-2025 |
| Dividend Yield | ★ 8.61% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 2.25 |
| Revenue | $146,948,000.00 | ★ $214,303,672.00 |
| Revenue This Year | $20.87 | $627.89 |
| Revenue Next Year | $4.29 | $40.95 |
| P/E Ratio | ★ N/A | $5.21 |
| Revenue Growth | 23.84 | ★ 1647.67 |
| 52 Week Low | $15.07 | $5.60 |
| 52 Week High | $20.88 | $17.43 |
Technical Indicators
Market Signals| Indicator | CTO | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 54.16 | 64.17 |
| Support Level | $17.81 | $10.90 |
| Resistance Level | $18.31 | $12.10 |
| Average True Range (ATR) | 0.25 | 0.49 |
| MACD | -0.06 | 0.25 |
| Stochastic Oscillator | 32.53 | 88.43 |
Price Performance
Historical ComparisonAbout CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties comprised of approximately 2.7 million square feet in diversified markets in the United States. Its portfolio of assets consists of Income Properties Portfolio, management services, Commercial Loan and Investments.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.